Navigation Links
Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer
Date:1/14/2014

es of future performance. Instead, they are based only on our current beliefs, expectations, observations and assumptions regarding the potential of our drug candidates and our technology. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) etirinotecan pegol is still in clinical development and the risk of failure is high and can unexpectedly occur at any time prior to regulatory approval for numerous reasons including safety and efficacy findings from the ongoing BEACON clinical study; (ii) the statements regarding the therapeutic potential of etirinotecan pegol are based on preclinical data and data from the completed Phase 2 clinical study and future results from the BEACON clinical study may not confirm these earlier findings; (iii) the timing of the commencement or end of clinical trials, target timeframe for the availability of clinical results, and the successful commercial launch of our drug candidates may be delayed or unsuccessful due to manufacturing challenges, changing standards of care, regulatory delay, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iv) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of our technology platform to potential new drug candidates such as etirinotecan pegol is therefore very uncertain and unpredictable and could unexpe
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
2. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
3. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
4. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
5. CAS REGISTRY(SM) surpasses 75 million small molecules
6. WuXi Manufacturing Facility Passes FDA Inspection
7. Tecfideras Patient Share at Three Months Postlaunch Surpasses That for Aubagio and Gilenya At the Same Stage of Their Launches
8. Emotivs Brainwear Technology To Track Cognitive Health Surpasses $1M Kickstarter Stretch Goal
9. The Leukemia & Lymphoma Society Co-Pay Assistance Fund Surpasses $200 Million
10. French Man with SynCardia Total Artificial Heart Surpasses Two Years of Support
11. NABPs .PHARMACY Proposal Passes Initial ICANN Evaluation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 29, 2014 Electrodes ... potential which can be amplified to diagnose as ... electrodes used in medical devices facilitate the detection ... from muscle cells and neurons of the patients. ... utilize the radiofrequency alternating current to perform minimally ...
(Date:10/30/2014)... BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today reported financial ... "During the quarter, we achieved a key ... securing a partner to accelerate the development and commercialization of ... we do not have a commercial presence while also retaining ... the value of PIXUVRI for CTI and help us achieve ...
(Date:10/30/2014)... YORK , Oct. 29, 2014 ... growth through 2013 with the introduction of new ... well-covered in Vaccines: The World Market. The Kalorama ... covering specifically commercialized vaccines and developmental vaccines for ... not only individuals, but also entire communities from ...
Breaking Medicine Technology:Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 2Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 3Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 4CTI BioPharma Reports Third Quarter 2014 Financial Results 2CTI BioPharma Reports Third Quarter 2014 Financial Results 3CTI BioPharma Reports Third Quarter 2014 Financial Results 4CTI BioPharma Reports Third Quarter 2014 Financial Results 5CTI BioPharma Reports Third Quarter 2014 Financial Results 6CTI BioPharma Reports Third Quarter 2014 Financial Results 7CTI BioPharma Reports Third Quarter 2014 Financial Results 8CTI BioPharma Reports Third Quarter 2014 Financial Results 9CTI BioPharma Reports Third Quarter 2014 Financial Results 10CTI BioPharma Reports Third Quarter 2014 Financial Results 11CTI BioPharma Reports Third Quarter 2014 Financial Results 12Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 2Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 3
... (Nasdaq: UPI ), a medical device company ... treat voiding dysfunctions, announced today that David Kaysen, Uroplasty,s ... and CFO, will present the Company,s business strategy and ... Conference at 3:30  PM PDT on Tuesday, August 17, ...
... SPRING, Md., Aug. 16 The U.S. Food ... of the drug midodrine hydrochloride, used to treat ... required post-approval studies that verify the clinical benefit ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ...
Cached Medicine Technology:Uroplasty to Present at Global Hunter Securities Inaugural Healthcare Conference 2FDA Proposes Withdrawal of Low Blood Pressure Drug 2FDA Proposes Withdrawal of Low Blood Pressure Drug 3
(Date:10/31/2014)... available in French . ... is common but fantasizing about golden showers is not. ... project that scientifically defines sexual deviation for the first ... universitaire en santé mentale de Montréal and Institut Philippe-Pinel ... theories about deviant sexual fantasies incorporate the concept of ...
(Date:10/30/2014)... group at the DFG Research Center for Regenerative Therapies ... (CRTD) demonstrated for the first time the in vitro ... dimensions from mouse embryonic stem cells. Correct spatial organization ... dorsal/ventral axis was observed., This study has been published ... Reports " on 30.10.2014 ., For many years Elly ...
(Date:10/30/2014)... Don Allred Insurance, a leading provider of ... North Carolina residents, is excited to announce the Grand ... Mall. The new branch has been up and running ... all facets of the insurance selection process from quote ... Allred couldn’t be happier with the timing of this ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Radio listeners ... raising questions about the impact of traditional radio commercials ... method most likely to influence a purchasing decision. , ... of 525 consumers conducted by radio marketing company CRN ... categories, isolating the results of respondents who indicated they ...
(Date:10/30/2014)... Dr. Joseph Furlin MD, a certified obstetrician ... practices; OB GYN in Melrose Park, IL and ... contains important information about each of the care services and ... forms in English and Spanish. The navigation of the ... the website provide Dr. Furlin’s patients with important information regarding ...
Breaking Medicine News(10 mins):Health News:Sexual fantasies: Are you normal? 2Health News:Sexual fantasies: Are you normal? 3Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:Allred Insurance Satellite Office Grand Opening 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2
... Team Cojo to fight PKD, LOS ANGELES, ... transplant, fashion critic and Entertainment Tonight correspondent,Steven "Cojo" ... million people,worldwide affected by Polycystic Kidney Disease (PKD)., ... common, life-threatening genetic,diseases, affecting more people than Down ...
... American Journal of Nursing (AJN) announced today ... Award is being given to Jean and Ric Edelman, ... generosity to nursing. The Award, recognizing individuals or ... and excellence in nursing practice, was presented on October ...
... Greater ... Flexibility, PITTSBURGH, ... that assist individuals with,significant speech, language and learning disabilities, announced the,release ... new release includes a range of new features that enhance,communication options, ...
... change as culprits , , WEDNESDAY, Oct. 29 (HealthDay News) ... infectious diseases, and that number could increase dramatically during ... delivered in a report, Germs Go Global: Why ... released Wednesday by the Trust for America,s Health (TFAH). ...
... researcher and director of the Institute for Cardiovascular Regeneration ... Advanced Grant, from the European Research Council to support ... will be investigating how to improve the healing process ... the repair of heart tissue. This research application is ...
... WASHINGTON, Oct. 29 CAQH, a nonprofit alliance ... healthcare,administration, announced today that the American Medical Association ... Information Exchange,(CORE) initiative., Joseph M. Heyman, MD, ... the,following statement of support for CORE: "The standardized ...
Cached Medicine News:Health News:Cojo to Hit the Streets of LA for 2008 Walk for PKD 2Health News:The American Journal of Nursing honors Jean and Ric Edelman 2Health News:The American Journal of Nursing honors Jean and Ric Edelman 3Health News:DynaVox Releases Software Version 1.05 for DynaVox V and Vmax 2Health News:DynaVox Releases Software Version 1.05 for DynaVox V and Vmax 3Health News:Threat From Infectious Diseases Growing 2Health News:Threat From Infectious Diseases Growing 3Health News:Promoting the healing process after a heart attack 2Health News:American Medical Association Endorses CAQH CORE Effort to Standardize and Streamline Patient Administrative Data Exchange 2
... Cement consists of a two ... bone cement liquid within a ... polyethylene bag,containing bone cement powder ... interiors of the blister pack,and ...
... Radiopaque Bone Cement consists of ... sterile,ampule containing bone cement liquid ... a sterile polyethylene bag,containing bone ... pouch. The interiors of the ...
A "doughy" type of bone cement intended for manual application....
... technology, such as a recessed scratch-resistant sapphire ... housings, this arthroscope has superior clarity and ... Steris and steam autoclaving or soaked in ... to fit ACMI, Wolf, Dyonics and Storz ...
Medicine Products: